AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,546 Increased By 137.4 (1.85%)
BR30 24,809 Increased By 772.4 (3.21%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)

imageKARACHI: A single member bench of Sindh High Court, comprising Justice Mohammad Shafi Siddiqui, through an order on Thursday overthrew the decision by the provincial health authorities to purchase costly hepatitis drug from two multinational companies (MNCs).

The bench acknowledging that this was depriving local pharma companies of level playing ground scraped tender to buy costly hepatitis medicine from MNCs.

Justice Mohammad Shafi Siddiqui who had reserved the judgement on March 6, announcing the same Thursday, termed the process of purchase of medicine illegal, unlawful and without legal grounds; scrapping the tender issued for purchase of medicine worth Rs 250 million.

The detailed judgement came on a petition filed by various local pharmaceutical firms against the rejection of their products used for the treatment of Hepatitis B and C.

Earlier, the court had rejected the plea by the health department for partial purchase of hepatitis medicine from multinationals on the grounds that the court was hearing the case on priority basis therefore limited purchase could not be allowed.

The health authorities had pleaded to relax the stay order on the purchase of injection so that 25 per cent of medicine costing around Rs. 60.2 million could be bought for 33,000 patients, of whom some 1,800 were at terminal stage.

Advocates Faisal Siddiqui, Shahid Memon and Abdus Sattar Pirzada, the counsel for the petitioners, told the court that the government was playing games with mala fide intentions to benefit certain influential, causing great losses to public exchequer and interest of poor hepatitis patients.

They questioned as to why many leading health institutions including Government of Balochistan and Government of AJK had been purchasing and using the locally produced medicines for decades with no complaints, if they were harmful to human health.

The counsel further argued that the government had issued licenses to the local national pharmaceutical firms to produce the drug, allowing it to sell the medicine in local market as well as to export it.

They said one of the drug rejected on quality grounds was the largest selling pharma item in the country and it was produced by Getz Pharma that was the only one in Pakistan having WHO recognition for its laboratory.

The counsel said that the government officials continued to misguide government, masses and the court for their ulterior motives to buy costly medicine from two major multinationals.

Copyright APP (Associated Press of Pakistan), 2015

Comments

Comments are closed.